DocLogic, the issue you’re describing is not about “terminal polarization strength” or different levels of maturity between the DCVax-L and DCVax-Direct dendritic cells. The filings are not drawing a biochemical distinction like that. What they are describing is a manufacturing distinction. The older Direct workflow used an early, partially manual process built around TFF and open handling. The updated Direct workflow will run on a closed automated system that the company is already validating. That system is Eden. The Q spells this out in the language that follows the TFF line, which includes writing new SOPs, qualifying Grade C cleanrooms, performing aseptic operator simulations, and running three consecutive PQQ batches. A sponsor does not redo an entire validation package for the older system. They do that only when transferring a product into the new commercial system that has not been used in the IND before.
Bosch’s NYAS deck confirms this directly. When he describes the manufacturing characteristics of DCVax-Direct, he lists properties that match Eden exactly. Uniformly immature cells, tightly controlled partial maturation, controlled activation sequences, predictable cytokine production, and a design built for automated scale. Those are Eden features, not legacy TFF features. He also states that Direct is manufactured in a closed and automated system designed to maximize therapeutic effects. There is no interpretation required. That line is Bosch’s literal wording. He is describing the next-generation platform, not the old manual one.
The wording in the Q about revising the IND is also being misread. That language does not suggest the issue is “resolved” in the sense you are implying. It simply means the IND paperwork is being updated to reflect the shift to the commercial platform. This is administrative, not biological. The sponsor must formally indicate which system is being used, and then demonstrate that the new system meets all qualification requirements. That is what the Q lays out step by step. It does not indicate confusion between two different dendritic-cell “types.” It indicates a transfer from an outdated workflow to the automated system that will be used going forward.
So the core point remains intact. Direct cannot stay on the legacy method because the biology and engineering of the new booster combinations and maturation logic do not allow it. The filings, Bosch’s slides, and the validation sequence all point in the same direction. Direct will run on Eden or an Eden-derivative commercial system, not on the old TFF workflow.
Bullish
Market Data 
Markets 
AI
